The emergence of Retatrutide ZPHC, at a dosage of 120mg, is sparking considerable excitement within the healthcare community. This innovative dual GIP and GLP-1 target medication appears to provide significant improvements in weight loss compared to previous therapies. Initial clinical trials have demonstrated substantial declines in body mass , co